Teladoc Health Expects Q4 Revenue Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy TDOC?
Source: seekingalpha
- Revenue Decline Expected: Teladoc Health anticipates a 0.8% year-over-year drop in Q4 revenue, with estimates around $635.33 million, reflecting challenges amid intensifying competition and macroeconomic uncertainty.
- Profitability Outlook: The management previously guided for 2025 consolidated revenue between $2.510 billion and $2.539 billion, with adjusted EBITDA projected at $270 million to $287 million, indicating a cautious stance on future profitability.
- Segment Performance Variance: The Integrated Care segment is expected to see revenue growth of 2.4% to 3.5%, while BetterHelp is projected to decline by 8% to 9.2%, highlighting performance disparities across business lines that could impact overall financial health.
- Risk Factors Highlighted: Teladoc cited persistent headwinds in the U.S. BetterHelp cash-pay segment, projecting a $3 million hit to adjusted EBITDA due to tariffs, which adds further uncertainty to the company's future financial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TDOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TDOC
Wall Street analysts forecast TDOC stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 5.300
Low
7.50
Averages
8.91
High
12.00
Current: 5.300
Low
7.50
Averages
8.91
High
12.00
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teladoc Health Reports Stronger-Than-Expected Quarterly Results
- Quarterly Performance Exceeds Expectations: Teladoc Health reported a quarterly loss of $0.14 per share, better than the expected loss of $0.18, with sales reaching $642.27 million, surpassing the forecast of $635.24 million, driven by a 24% increase in other revenue streams despite a 4% decline in access fees revenue.
- Cautious Future Outlook: The company expects a first-quarter 2026 loss between $0.35 and $0.45, with sales projected at $598 million to $620 million, both below consensus estimates of $0.25 and $633.75 million, indicating challenges in the current economic environment.
- Analyst Rating Changes: Deutsche Bank upgraded Teladoc from Hold to Buy with a price target of $11, reflecting confidence in the company's valuation; however, BTIG maintained a Neutral rating, expressing caution due to market competition and macroeconomic conditions despite acknowledging decent quarterly results.
- Stock Price Analysis: Teladoc shares are currently trading at $5.59, 21.8% above the 20-day simple moving average but 12.5% below the 100-day moving average, indicating short-term strength while facing long-term pressures, with a 40.65% decline over the past 12 months.
See More
Union Square Capital Sells Entire Stake in Mohawk Industries
- Share Sale Details: Union Square Park Capital Management disclosed in an SEC filing that it sold its entire 40,000-share position in Mohawk Industries during Q4 2026, with the previous stake valued at $5.1 million, representing 1.8% of its reported assets.
- Market Performance Analysis: Mohawk Industries' stock is currently priced at $132.60, reflecting a 9.6% increase over the past year, yet it remains 62% below its previous peak, indicating struggles for growth in a weak housing market.
- Financial Overview: Mohawk Industries reported a TTM revenue of $10.8 billion and a net income of $369.9 million, with a market capitalization of $8.2 billion, showcasing its strong position in the global flooring market, although management noted a 3% year-over-year revenue decline last quarter.
- Investment Strategy Shift: Following the sale of its Mohawk stake, Union Square increased its investment in RH, indicating a strategic shift in seeking undervalued stocks and potentially better return prospects in other investments.
See More
Teladoc Health Stock Soars After Beating Earnings Estimates
- Earnings Beat: Teladoc Health's latest earnings report exceeded market expectations, leading to a stock price surge that reflects the company's strong performance and sustained demand in the telehealth sector.
- Cautious 2026 Guidance: Despite robust current results, the company has adopted a cautious outlook for 2026, which may impact investor confidence and necessitate close monitoring of future market dynamics and strategic adjustments.
- Mixed Analyst Views: Analysts have divergent opinions on Teladoc's prospects, with some maintaining optimistic ratings while others express reservations about future growth, potentially leading to stock price volatility.
- Positive Market Reaction: Despite the cautious long-term guidance, the positive investor response to the company's current performance indicates that the market remains optimistic about Teladoc's long-term potential in the telehealth industry, which may attract more capital inflows.
See More
Deutsche Bank Upgrades Teladoc to Buy with $11 Price Target
- Rating Upgrade: Deutsche Bank upgraded Teladoc from Hold to Buy with a price target of $11, representing a 107% upside from Monday's closing price of $5.3, indicating strong confidence in Teladoc's current valuation.
- Positive Market Reaction: Teladoc's shares surged over 10% in pre-market trading on Tuesday, and if this level holds, the stock could open at its highest price since January 26, 2026, reflecting optimistic investor sentiment regarding the company's future prospects.
- Acquisition Impact: The acquisition of Talkspace by UHS, expected to close in Q3 2026, is viewed by Deutsche Bank as a “clear positive for Teladoc,” potentially providing a roadmap for a future exit scenario and enhancing its market position.
- Investor Sentiment Shift: Retail sentiment on Stocktwits shifted from bearish to bullish over the past 24 hours, with users expressing that Teladoc's market value is undervalued, showcasing confidence in the company's growth potential.
See More
Deutsche Bank Upgrades Teladoc to Buy, Citing Valuation and Growth Prospects
- Rating Upgrade: Deutsche Bank upgraded Teladoc from Hold to Buy, with analyst George Hill citing a compelling valuation and improving prospects for the BetterHelp business, which is expected to drive stock price appreciation.
- Business Outlook: Although BetterHelp has been shrinking, Teladoc has a stabilization and growth plan in place, and the analyst believes this will provide long-term growth potential, maintaining a price target of $11.
- Market Performance: Teladoc's stock has declined over 40% in the past 12 months and is rated Hold on Wall Street, indicating market caution regarding its future performance.
- Future Projections: Teladoc projects revenue between $2.47 billion and $2.59 billion for 2026 while advancing AI, insurance, and international growth, demonstrating the company's strategic intent for diversified development.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Teladoc Health Reports Stronger-Than-Expected Quarterly Results
- Quarterly Performance Exceeds Expectations: Teladoc Health reported a quarterly loss of $0.14 per share, better than the expected loss of $0.18, with sales reaching $642.27 million, surpassing the forecast of $635.24 million, driven by a 24% increase in other revenue streams despite a 4% decline in access fees revenue.
- Cautious Future Outlook: The company expects a first-quarter 2026 loss between $0.35 and $0.45, with sales projected at $598 million to $620 million, both below consensus estimates of $0.25 and $633.75 million, indicating challenges in the current economic environment.
- Analyst Rating Changes: Deutsche Bank upgraded Teladoc from Hold to Buy with a price target of $11, reflecting confidence in the company's valuation; however, BTIG maintained a Neutral rating, expressing caution due to market competition and macroeconomic conditions despite acknowledging decent quarterly results.
- Stock Price Analysis: Teladoc shares are currently trading at $5.59, 21.8% above the 20-day simple moving average but 12.5% below the 100-day moving average, indicating short-term strength while facing long-term pressures, with a 40.65% decline over the past 12 months.
See More
Union Square Capital Sells Entire Stake in Mohawk Industries
- Share Sale Details: Union Square Park Capital Management disclosed in an SEC filing that it sold its entire 40,000-share position in Mohawk Industries during Q4 2026, with the previous stake valued at $5.1 million, representing 1.8% of its reported assets.
- Market Performance Analysis: Mohawk Industries' stock is currently priced at $132.60, reflecting a 9.6% increase over the past year, yet it remains 62% below its previous peak, indicating struggles for growth in a weak housing market.
- Financial Overview: Mohawk Industries reported a TTM revenue of $10.8 billion and a net income of $369.9 million, with a market capitalization of $8.2 billion, showcasing its strong position in the global flooring market, although management noted a 3% year-over-year revenue decline last quarter.
- Investment Strategy Shift: Following the sale of its Mohawk stake, Union Square increased its investment in RH, indicating a strategic shift in seeking undervalued stocks and potentially better return prospects in other investments.
See More
Teladoc Health Stock Soars After Beating Earnings Estimates
- Earnings Beat: Teladoc Health's latest earnings report exceeded market expectations, leading to a stock price surge that reflects the company's strong performance and sustained demand in the telehealth sector.
- Cautious 2026 Guidance: Despite robust current results, the company has adopted a cautious outlook for 2026, which may impact investor confidence and necessitate close monitoring of future market dynamics and strategic adjustments.
- Mixed Analyst Views: Analysts have divergent opinions on Teladoc's prospects, with some maintaining optimistic ratings while others express reservations about future growth, potentially leading to stock price volatility.
- Positive Market Reaction: Despite the cautious long-term guidance, the positive investor response to the company's current performance indicates that the market remains optimistic about Teladoc's long-term potential in the telehealth industry, which may attract more capital inflows.
See More
Deutsche Bank Upgrades Teladoc to Buy with $11 Price Target
- Rating Upgrade: Deutsche Bank upgraded Teladoc from Hold to Buy with a price target of $11, representing a 107% upside from Monday's closing price of $5.3, indicating strong confidence in Teladoc's current valuation.
- Positive Market Reaction: Teladoc's shares surged over 10% in pre-market trading on Tuesday, and if this level holds, the stock could open at its highest price since January 26, 2026, reflecting optimistic investor sentiment regarding the company's future prospects.
- Acquisition Impact: The acquisition of Talkspace by UHS, expected to close in Q3 2026, is viewed by Deutsche Bank as a “clear positive for Teladoc,” potentially providing a roadmap for a future exit scenario and enhancing its market position.
- Investor Sentiment Shift: Retail sentiment on Stocktwits shifted from bearish to bullish over the past 24 hours, with users expressing that Teladoc's market value is undervalued, showcasing confidence in the company's growth potential.
See More
Deutsche Bank Upgrades Teladoc to Buy, Citing Valuation and Growth Prospects
- Rating Upgrade: Deutsche Bank upgraded Teladoc from Hold to Buy, with analyst George Hill citing a compelling valuation and improving prospects for the BetterHelp business, which is expected to drive stock price appreciation.
- Business Outlook: Although BetterHelp has been shrinking, Teladoc has a stabilization and growth plan in place, and the analyst believes this will provide long-term growth potential, maintaining a price target of $11.
- Market Performance: Teladoc's stock has declined over 40% in the past 12 months and is rated Hold on Wall Street, indicating market caution regarding its future performance.
- Future Projections: Teladoc projects revenue between $2.47 billion and $2.59 billion for 2026 while advancing AI, insurance, and international growth, demonstrating the company's strategic intent for diversified development.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
